Potbelly: Q1 Earnings Snapshot
The Chicago-based company said it had a loss of less than 1 cent on a per-share basis.
The sandwich restaurant operator posted revenue of $113.7 million in the period.
_____
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Elbit Systems Ltd (ESLT) Q2 2025 Earnings Call Highlights: Robust Growth and Strategic Advances
Revenue: $1.973 billion in Q2 2025, up from $1.626 billion in Q2 2024. Gross Margin: GAAP gross margin at 24% of revenues; non-GAAP gross margin at 24.4% of revenues. Operating Income: GAAP operating income of $157.8 million (8% of revenues); non-GAAP operating income of $175.1 million (8.9% of revenues). Net R&D Expenses: $129.7 million or 6.6% of revenues. Marketing and Selling Expenses: $91.5 million or 4.6% of revenues. G&A Expenses: $93.9 million or 4.8% of revenues. Financial Expenses: $31.2 million. Tax Expense: $7.1 million with an effective tax rate of 5.6%. Diluted EPS: GAAP diluted EPS of $2.69; non-GAAP diluted EPS of $3.23. Free Cash Flow: $71 million generated in the quarter. Order Backlog: $23.8 billion as of June 30, 2025. Cash Flow from Operating Activities: $304 million for the six months ended June 30, 2025. Dividend: Increased to $0.75 per share, a 50% increase from last year. Segment Revenue Growth: Aerospace up 12%, C4I and Cyber up 21%, ISTAR and EW up 15%, Land up 45%, Elbit Systems of America up 4%. Warning! GuruFocus has detected 3 Warning Signs with LUCD. Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Elbit Systems Ltd (NASDAQ:ESLT) reported strong double-digit year-over-year growth across all business segments and geographies, particularly in Europe. The company's backlog increased by 12% from the corresponding quarter in 2024, reaching $23.8 billion. Free cash flow generated in the quarter totaled $71 million, indicating strong cash management. Elbit Systems Ltd (NASDAQ:ESLT) successfully raised $573 million through a share offering, with demand reaching three times the initial amount. The company announced a significant contract worth $1.625 billion to deliver a range of defense solutions to a European country over the next five years. Negative Points General and administrative expenses increased to $93.9 million, up from $68.7 million in the second quarter of 2024, due to one-time expenses. Financial expenses rose to $31.2 million, impacted by exchange rate fluctuations. The effective tax rate decreased to 5.6% from 13.2% in the second quarter of 2024, which may not be sustainable long-term. Despite strong performance, the company faces geopolitical challenges, particularly in regions like France where there is resistance to buying from Israeli companies. There are ongoing supply chain challenges, particularly in the development and delivery of high-power laser solutions. Q & A Highlights Q: Going into the back half of the year, how should we think about the margin expansion and what's going to drive that? A: We are focusing on expanding our margins through various efforts, including the implementation of our new ERP system and operational leverage. Over the past three years, we've achieved around 3% margin expansion, and we are committed to continuing this trend. Q: Could you provide updates on R&D or what you're seeing in the supply chain, specifically for FRM? A: We are developing high-power laser sources for a solution led by Rafael, with deliveries starting soon. We expect to deploy the system by the end of this year. Additionally, we are working on prime and airborne high-power solutions for the Israeli Air Force, with significant international interest. Q: How do we think about the deceleration in the second half and outlook for 2026 as you think about capacity utilization and new orders? A: Our internal target for 2025 is mid-teens growth, and we aim for double-digit growth in 2026. The recent contract announcements will support the backlog needed for this growth, although we do not provide formal guidance. Q: Can you give details on the segments, particularly the land segment's 45% growth in Q2? A: All segments performed well, with the land segment showing 45% year-over-year growth. This segment benefits from high demand for products like munitions, Iron Fist, Sigma, and Rampage missiles. We expect continued revenue growth and margin expansion in this segment. Q: What are the company's plans for future development of UAS counter-drone measures, and potential exports to Europe and the US? A: We have a system called Wigan, which integrates various detection and counter technologies. It has been successfully used by the IDF and exported to countries like the Netherlands and other NATO members. We believe it is one of the most advanced solutions available. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
28 minutes ago
- Yahoo
Vireo Growth Inc (VREOF) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansions
Pro Forma Revenue: $90.7 million. Adjusted EBITDA: $23.2 million, with a margin of approximately 25%. Second Quarter GAAP Revenue: $48.1 million, a 91.4% increase year over year. Gross Margin: 51.6%, a reduction of 260 basis points compared to the prior year quarter. SG&A Expenses: $12.2 million, 25.4% of sales, an improvement of 480 basis points compared to Q2 last year. Adjusted Operating Income: $11.3 million, 23.5% of sales. Cash on Hand: $106.2 million at the end of Q2. Total Current Assets: $186.2 million, excluding New York assets held for sale and income taxes receivable. Total Current Liabilities: $51.8 million, excluding New York liabilities held for sale and refinanced debt. Corporate SG&A Costs: $1.8 million, a reduction of approximately 40% from the prior year quarter. Shares Outstanding: 158,617,377 shares on the Treasury method basis. Warning! GuruFocus has detected 9 Warning Signs with VREOF. Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Vireo Growth Inc (VREOF) reported a significant increase in GAAP revenue, up 91.4% year over year, driven by contributions from recent merger transactions. The company successfully closed three merger transactions, expanding its operational portfolio to six states and improving profitability and cash generation. Vireo Growth Inc (VREOF) completed a $153 million refinancing event, reducing annual interest expenses by approximately $10 million and increasing cash on hand to over $100 million. The company achieved an adjusted EBITDA margin of approximately 25%, with adjusted EBITDA of $23.2 million. SG&A expenses, excluding severance, improved by 480 basis points compared to the previous year, indicating better cost management. Negative Points GAAP gross margin was negatively impacted by termination fees related to a prior agreement, resulting in a reduction of 260 basis points compared to the prior year quarter. The company's performance in Minnesota was softer, affecting overall gross margin. Vireo Growth Inc (VREOF) faces uncertainty regarding the timing of adult-use cannabis sales in Minnesota, which could impact future revenue. The company is still awaiting regulatory approval for the divestment of New York assets, which could delay strategic plans. Price deflation and competition from hemp in markets like Nevada and Missouri pose challenges to maintaining market share and profitability. Q & A Highlights Q: Can you discuss the impact of the licensing agreement with Curio on your New York assets and distribution network? A: John Mazarakis, CEO & Co-Executive Chairman: The partnership with Curio does not affect the divestiture of our New York assets. Curio is a leading brand in the nutraceutical space, and we see no cannibalization with our current SKUs. We are optimistic about this relationship. Q: With the recent refinancing, what are your capital management priorities, and are there any M&A opportunities on the horizon? A: John Mazarakis, CEO & Co-Executive Chairman: We are engaging in M&A discussions, focusing on both distressed and mature spaces. While we are hopeful for M&A in the next 12 to 24 months, our primary focus remains on organic growth and achieving positive free cash flow at the unit level. Q: Can you provide an update on the Arches platform and its potential impact on growth? A: John Mazarakis, CEO & Co-Executive Chairman: We are working on deploying the Arches delivery platform. Delivery is available in all states where it is permitted, and we continue to invest in this service as we believe in its potential. Q: What preparations are being made for recreational cannabis sales in Minnesota, and how do you foresee the rollout? A: John Mazarakis, CEO & Co-Executive Chairman: We anticipate a shortage of supply in Minnesota, with initial supply coming from us and GTI. We are working with the state to ensure readiness and expect to begin adult-use sales in the second half of this year. Our retail footprint remains limited to eight locations. Q: Can you clarify the situation with your New York assets and potential partnerships there? A: John Mazarakis, CEO & Co-Executive Chairman: We are committed to a buyer for our New York assets, pending regulatory approval. Our partners have a wide network, and we aim to become the largest supplier of indoor flower in New York, leveraging this partnership. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
28 minutes ago
- Yahoo
Kamada Ltd (KMDA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Increased ...
Total Revenue (First Half 2025): $88.8 million, up 11% year over year. Total Revenue (Q2 2025): $44.8 million, up 5% year over year. Adjusted EBITDA (First Half 2025): $22.5 million, up 35% year over year, representing a 25% margin. Adjusted EBITDA (Q2 2025): $10.9 million, up 20% year over year. Gross Profit (Q2 2025): $18.9 million with a 42% margin. Gross Profit (First Half 2025): $39.7 million with a 45% margin. Net Income (Q2 2025): $7.4 million or $0.13 per diluted share. Net Income (First Half 2025): $11.3 million or $0.19 per diluted share. Operating Expenses (Q2 2025): $11.9 million. Cash Provided by Operating Activities (Q2 2025): $8 million. Cash Balance (End of First Half 2025): $66 million. Annual Revenue Guidance 2025: $178 million to $182 million. Adjusted EBITDA Guidance 2025: Increased to $40 million to $44 million. Warning! GuruFocus has detected 4 Warning Sign with KMDA. Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Kamada Ltd (NASDAQ:KMDA) reported strong financial results for the first half of 2025, with total revenues of $88.8 million, representing an 11% year-over-year increase. Adjusted EBITDA for the first half of 2025 was $22.5 million, up 35% year-over-year, indicating improved profitability. The company increased its adjusted EBITDA guidance for 2025 to between $40 million and $44 million, reflecting confidence in continued profitable growth. Kamada Ltd (NASDAQ:KMDA) is advancing its PIVOTAL phase 3 inhaled clinical program, which could lead to significant future growth opportunities. The company successfully launched its first biosimilar product in Israel and plans to launch two additional biosimilars later this year, contributing to future revenue growth. Negative Points Gross profit margins decreased in the second quarter of 2025 compared to the same period in 2024, due to changes in product and territory sales mix. Operating expenses, although managed well, still represent a significant portion of revenues, which could impact future profitability if not controlled. The company's net income, while improved, is still subject to fluctuations due to changes in financial and tax expenses. The competitive landscape for Kamada Ltd (NASDAQ:KMDA)'s inhaled AAT program is evolving, with other companies developing alternative technologies that could impact market share. The company's cash position, although strong, has declined over the last couple of quarters, which may limit the scale of future business development and M&A activities. Q & A Highlights Q: Can you provide insights into the dynamics behind KEDRAB and CYTOGAM, which have been growth drivers in the past? Are they performing as expected? A: Amir London, CEO: KEDRAB and CYTOGAM are performing according to expectations. KEDRAB is supplied based on inventory management, and CYTOGAM is progressing as planned. Growth is anticipated once additional clinical data is available. The diversity of our portfolio, including products like GLASSIA and VARIZIG, supports our continued growth. Q: With a solid cash position, is it sufficient for impactful business development? How do you balance internal investments and external business development? A: Amir London, CEO: We plan to use existing cash and have additional funding sources if needed. We are focused on commercial stage assets, particularly in plasma-derived products and specialty pharma. We are actively screening multiple targets and expect meaningful impact on our 2026 performance. Q: Can you describe the competitive landscape for the inhaled AAT program? Are there developments that might change the market opportunity? A: Amir London, CEO: Our inhaled program is the most advanced in terms of efficacy studies. The market is growing, and we expect it to be a $2 billion market by the time we have study results. Our technology offers better ease of use and quality of life, positioning us as a strong competitor. Q: Was there any one-time sales impact in the distribution revenue segment this quarter? How should we view this channel going forward? A: Amir London, CEO: There were no one-time sales. The launch of the biosimilar product builds on our existing infrastructure, and we expect continued growth. This will help improve our margins over the next few years. Q: What was responsible for the tax credit in the June quarter, and what do you expect the tax rate to be in the future? A: Chaime Orlev, CFO: Fluctuations in currency exchange affected our tax results. We anticipate utilizing all tax loss carryforwards by the end of 2025, moving into tax payments. The effective tax rate is expected to be between 20% and 25% in 2026 and beyond. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
